Zacks Investment Research lowered shares of Edap Tms S.A. (NASDAQ:EDAP) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning. <\/p>\n
According to Zacks, EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. <\/p>\n
Separately, TheStreet raised Edap Tms from a sell rating to a hold rating in a research note on Tuesday, September 27th. <\/p>\n
Edap Tms (NASDAQ:EDAP) traded up 2.64% on Tuesday, hitting $3.50. The stock had a trading volume of 110,584 shares. The stock has a 50 day moving average price of $3.16 and a 200 day moving average price of $3.03. Edap Tms has a 1-year low of $2.43 and a 1-year high of $4.80. The company has a market cap of $100.54 million, a P\/E ratio of 8.93 and a beta of 1.29. <\/p>\n
An institutional investor recently raised its position in Edap Tms stock. Wells Fargo & Company MN raised its position in shares of Edap Tms S.A. (NASDAQ:EDAP) by 1.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 193,655 shares of the companys stock after buying an additional 2,000 shares during the period. Wells Fargo & Company MN owned approximately 0.67% of Edap Tms worth $562,000 as of its most recent filing with the SEC. 9.56% of the stock is owned by hedge funds and other institutional investors. <\/p>\n
Edap Tms Company Profile <\/p>\n
EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors. <\/p>\n
Get a free copy of the Zacks research report on Edap Tms (EDAP) <\/p>\n
For more information about research offerings from Zacks Investment Research, visit Zacks.com <\/p>\n
<\/p>\n
Read the original post: <\/p>\n
Stocks: Edap Tms SA (EDAP) Lowered to Sell at Zacks Investment Research - Petro Global News 24<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Zacks Investment Research lowered shares of Edap Tms S.A. Continue reading